Re: Share Price too many large share sales by directors for my liking
Re: Share Price Maybe it is is down to President Trump trying to remove obama care with his new healthcare bill, voting later today.
Share Price Can anyone comment on the decline in the share price? Appreciate any commentary.
results tomorrow .
Re: Trading Statement No...Trading statement on the 25th.Ambiorix.
Trading Statement Obviously not 19th.January ???
A bit of hidden good news in anticipation of the up and coming half year trading update on 19th January
Re: Re: Interesting to have that info Ambiorix1. Thankyou,
Re: On 30 december Innocoll Holdings announced that it has received a Refusal to File letter from the U.S. Food and Drug Administration for Xaracoll, the company's product candidate for the treatment of postsurgical pain. Xaracoll belongs to the Bupivacaine family. Clinigen just signed an agreement for the distribution of BioQ's Ropivacaine which is also a post-operative pain management product. Bad news for Innocoll is probably good news for BIOQ pharma and indirectly also positive for Clinigen.Ambiorix.
Very volatile this share
Re: Well done Clinigen Just wished had topped up the days after Brexit!Like you said pharmaspecialist, debt down is always great to see, and the integration of the purchased businesses is being managed very well, excellent Results.
Well done Clinigen Excellent results out today and I think justify the 11% share price increase at the time of writing. The results have also been achieved whilst lowering debt so they are real. I think leadership of a niche within the pharmaceutical sector is a very nice place to be, and I would congratulate the board and management on this strategy.
Results Looking forward to Wednesday's results.
Re: Was this really worth a press release? After major decline in recent weeks, must be huge news... look what it's done to the share price today... !!
Was this really worth a press release? I can't help but think that producing a drug in a bag instead of a bottle is not exactly major news, particularly as no relevant financial figures are given! Still, better to provide too much information than too little.